Mir-17 and miR-93 promote tumor progression by targeting p21 in patients with chordoma
OncoTargets and Therapy May 17, 2021
Dong W, Li J, Dong X, et al. - Researchers investigated the role of two micorRNAs (miRNAs), miR-17 and miR-93, as well as their potential mechanisms in chordoma. They used quantitative real-time polymerase chain reaction, Kaplan–Meier survival curve, and Cox regression analysis to determine the expression as well as prognostic value of miR-17 and miR-93. They found chordoma tissues exhibited high expression of miR-17/93, which was linked with poor prognosis. A contributor to cell proliferation, colony formation, and invasion, was overexpression of miR-17/93. Findings showed that miR-17/93 exerts a potential oncogenic impact on chordoma progression, and miR-17/93-p21 axis was indicated as a promising treatment target in chordoma.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries